U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C21H17F4NO3S2
Molecular Weight 471.488
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of GW-0742

SMILES

CC1=C(CSC2=CC(C)=C(OCC(O)=O)C=C2)SC(=N1)C3=CC=C(C(F)=C3)C(F)(F)F

InChI

InChIKey=HWVNEWGKWRGSRK-UHFFFAOYSA-N
InChI=1S/C21H17F4NO3S2/c1-11-7-14(4-6-17(11)29-9-19(27)28)30-10-18-12(2)26-20(31-18)13-3-5-15(16(22)8-13)21(23,24)25/h3-8H,9-10H2,1-2H3,(H,27,28)

HIDE SMILES / InChI

Molecular Formula C21H17F4NO3S2
Molecular Weight 471.488
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/26508837 | https://www.ncbi.nlm.nih.gov/pubmed/21270242

GW0742, also known as GW610742, is a potent and highly selective PPARβ/δ agonist, with IC50 of 1 nM, with 1000-fold selectivity over hPPARα and hPPARγ. GW0742 treatment has a prominent anti-inflammatory effect in 5XFAD mice and suggests that PPARδ agonists may have therapeutic utility in treating AD. GW0742 has the ability to improve glucose homeostasis in diabetic rats through activation of PPAR-δ. Therefore, PPAR-δ is a good target for the development of antidiabetic drugs in the future.

Approval Year

PubMed

PubMed

TitleDatePubMed
Novel selective small molecule agonists for peroxisome proliferator-activated receptor delta (PPARdelta)--synthesis and biological activity.
2003 May 5
Development of PPAR-agonist GW0742 as antidiabetic drug: study in animals.
2015
Activation of the nuclear receptor PPARδ is neuroprotective in a transgenic mouse model of Alzheimer's disease through inhibition of inflammation.
2015 Jan 16
PPARδ agonist GW0742 ameliorates Aβ1-42-induced hippocampal neurotoxicity in mice.
2016 Jun
Patents

Sample Use Guides

Mice: GW0742 (30 mg/kg) significantly decreases protein and mRNA levels of the pro-inflammatory cytokines IL-6, IL-1beta and TNFalpha in bronchial alveolar lavage fluid of mice.
Route of Administration: Oral
GW0742 (0.2 uM and 1 uM) treatment results in significant increases in reporter activity of PPARβ/δ in N/TERT-1 keratinocytes. GW0742 (1 uM) results in significant inhibition in the average number of N/TERT-1 keratinocytes. GW0742 (1 uM) results in an increase in the number of cells in the G1 phase and a decrease in the number of cells in the S phase.
Substance Class Chemical
Created
by admin
on Sat Dec 16 09:41:11 UTC 2023
Edited
by admin
on Sat Dec 16 09:41:11 UTC 2023
Record UNII
4PZK9FJC4Z
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
GW-0742
Common Name English
GW0742
Common Name English
(4-(((2-(3-FLUORO-4-(TRIFLUOROMETHYL)PHENYL)-4-METHYL-1,3-THIAZOL-5-YL)METHYL)SULFANYL)-2-METHYLPHENOXY)ACETIC ACID
Systematic Name English
Code System Code Type Description
WIKIPEDIA
GW0742
Created by admin on Sat Dec 16 09:41:11 UTC 2023 , Edited by admin on Sat Dec 16 09:41:11 UTC 2023
PRIMARY
FDA UNII
4PZK9FJC4Z
Created by admin on Sat Dec 16 09:41:11 UTC 2023 , Edited by admin on Sat Dec 16 09:41:11 UTC 2023
PRIMARY
PUBCHEM
9934458
Created by admin on Sat Dec 16 09:41:11 UTC 2023 , Edited by admin on Sat Dec 16 09:41:11 UTC 2023
PRIMARY
EPA CompTox
DTXSID9040760
Created by admin on Sat Dec 16 09:41:11 UTC 2023 , Edited by admin on Sat Dec 16 09:41:11 UTC 2023
PRIMARY
CAS
317318-84-6
Created by admin on Sat Dec 16 09:41:11 UTC 2023 , Edited by admin on Sat Dec 16 09:41:11 UTC 2023
PRIMARY
Related Record Type Details
TARGET -> AGONIST
Related Record Type Details
ACTIVE MOIETY